Effect of darunavir on lipid profile in HIV-infected patients. - Wikidata - awgldk - TriplyDB

Effect of darunavir on lipid profile in HIV-infected patients.

Effect of darunavir on lipid profile in HIV-infected patients.

http://www.wikidata.org/entity/Q38058385

about

Cardiovascular disease risk in an aging HIV population: not just a question of biology.Epidemiology and management of antiretroviral-associated cardiovascular disease.Dysregulation of Endoplasmic Reticulum Stress and Autophagic Responses by the Antiretroviral Drug Efavirenz.Infectious and Non-infectious Etiologies of Cardiovascular Disease in Human Immunodeficiency Virus Infection Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.Darunavir: a review of its use in the management of HIV-1 infection.Darunavir: A Review in Pediatric HIV-1 Infection.Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).Metabolic health across the body mass index spectrum in HIV-Infected and HIV-Uninfected Men.Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.

P2860

Q35064091-8288567E-C622-40CB-9CCF-727A4CBE8533 Q35338096-20B200FF-91F8-4F7D-AB27-66679C40FD6C Q35897840-14A4551C-9F39-4AFB-A4DC-65412EA4A07B Q37195784-149A1933-FBAF-42D4-830C-098C9F7F6DCC Q37250997-B436E386-558C-4AE0-95E2-14164BEEF66B Q38108736-AA2A8341-7AA2-46B9-8BC0-28BD2BEDD1FA Q38171346-2A11E644-7F37-4900-AA22-8A37BF749B69 Q38577433-D1B19E0E-50F9-4B90-B22F-D656D596641B Q38723259-32AFA156-F029-483B-8865-1350A63EE1D8 Q40145206-03AFFED9-8B7E-4276-853C-F472F4CFD0EE Q41934612-C84C6FC3-3CCA-4B6C-8F39-B5B396894DC6 Q47602387-7DA78BC5-7DEF-4DA5-AFBE-8A469583AC6B

P2860

Effect of darunavir on lipid profile in HIV-infected patients.

http://www.wikidata.org/entity/Q38058385

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Effect of darunavir on lipid profile in HIV-infected patients.

@en

type

label

Effect of darunavir on lipid profile in HIV-infected patients.

@en

prefLabel

Effect of darunavir on lipid profile in HIV-infected patients.

@en

P1433

Q38058385-5D36EEF4-FDA3-4EFC-AB34-ECFC68719EFC

P1476

Q38058385-1FF878BD-6545-4C2F-B45C-BAEC5952BF03

P2093

Q38058385-32697D6A-3E83-4837-B78D-F51156CE5548

Q38058385-4BEA3BA0-B019-4A5F-909A-9B009B8F3388

Q38058385-89E2FDB5-7F75-4018-AEC5-174C05064516

Q38058385-93371FFB-ADAA-4553-A612-512C06F7FAB2

P2860

Q38058385-05D8FC76-0A34-42D1-B978-24A6C2AE56C5

Q38058385-0682443A-8E59-4B60-9115-C8E9E553EC92

Q38058385-0770F564-9B57-47E6-AAD9-3F8288D1720B

Q38058385-0AD766B4-9E59-4D09-B545-1FF24AFDB048

Q38058385-0C3741FF-84DE-4405-84C9-ECB0E98AE961

Q38058385-0DEC2BED-7549-45DD-9A12-361D0B6B2EB7

Q38058385-13DDD4B5-0460-4D60-98A0-42326FB8326F

Q38058385-15B98417-A6C5-4C04-8367-AB7D8D353FBF

Q38058385-1C3E652F-F18D-4A12-8A7A-BF7EF360BF64

Q38058385-22228F97-5C94-4132-81C9-FAC75F657ABF

P304

Q38058385-9874DA29-2027-491E-87AB-F469731A359C

P31

Q38058385-C1AF5EB8-568E-4BE1-B76F-9B4BEFFE0A7F

P356

Q38058385-C521C400-F767-4786-BB7A-832DDCEFF5A9

P433

Q38058385-4D6D9DA2-AFB9-4EC2-88D6-36170EE3C422

P478

Q38058385-8D2B3A54-B7E0-4078-A16C-6FD0F429E5D8

P577

Q38058385-2D913149-5329-4A20-B87F-EE235DF735B9

P5875

Q38058385-0B7E5104-A565-4EFB-ADF8-BCF0980A990E

P698

Q38058385-C67DB3A8-BBF9-466E-9EF8-AE122ACDAC35

P356

P1433

HIV Clinical Trials

P1476

Effect of darunavir on lipid profile in HIV-infected patients.

@en

P2093

Edgar Turner Overton

http://www.w3.org/2001/XMLSchema#string

Eduardo Arathoon

http://www.w3.org/2001/XMLSchema#string

Ezio Baraldi

http://www.w3.org/2001/XMLSchema#string

Frank Tomaka

http://www.w3.org/2001/XMLSchema#string

P2860

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

CD4+ count-guided interruption of antiretroviral treatment

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.

Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection

P304

256-270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HCT1305-256

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233328236

http://www.w3.org/2001/XMLSchema#string

P698

23134626

http://www.w3.org/2001/XMLSchema#string